Biogen Inc. BIIB NASDAQ

Biogen Inc. (BIIB) reported total assets of $29.44B and total liabilities of $11.18B for fiscal year 2025, resulting in total equity of $18.26B.

The company held $3.82B in cash and short-term investments. Total debt stood at $6.95B, with net debt of $3.94B. The Debt-to-Equity (D/E) ratio was 0.38 (conservative).

Current ratio is 2.68, indicating strong short-term liquidity. Interest coverage is 7.6x (adequate).

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.38, current ratio of 2.68, interest coverage 7.6x — balance sheet is strong
• MOAT (65/100) — Total assets $29.44B and equity $18.26B support the company's competitive scale
• VALUE (47/100) — Debt-to-Equity 0.38 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 60/100 with 2/7 criteria passed.

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

MRK

Merck & Co., Inc.

$119.96

-0.16%

NVS

Novartis AG

$153.38

-0.71%

AMGN

Amgen Inc.

$350.95

+0.32%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

PFE

Pfizer Inc.

$27.13

-0.77%

GSK

GSK plc

$59.18

+0.41%